|
|
Article: Study Shows Nighttime Dosing of Biovail's Cardizem LA Lowers Blood Pressure and Other Risks More Than Nighttime Dosing of Altace.
- Article from:
- Business Wire
- Article date:
- May 16, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
NEW YORK--(BUSINESS WIRE)--May 16, 2003
New Graded-Release Diltiazem Formulation Outperforms "ACE" from HOPE
Trial
In one of the first head-to-head trials to compare the advantages of two blood pressure treatments administered at night, Biovail Corporation's (NYSE, TSX: BVF) Cardizem(R) LA outperformed Altace(R), the nation's top selling branded ACE inhibitor, on trial endpoints including reductions in early-morning and 24-hour blood pressure, heart rate and rate-pressure product, a strong correlate of myocardial oxygen consumption.
The benefits of Cardizem(R) LA, a new graded-release ...